Use of imipramine hydrochloride for treatment of urospermia in a stallion with a dysfunctional bladder.
An 8-year-old stallion was evaluated because of recurrent urinary tract infections and chronic intermittent urospermia. After extensive diagnostic testing, it was hypothesized that the stallion had a reflex dyssynergia of the bladder and urethral sphincter. Initial attempts to manage the urospermia included semen fractionation, semen collection after voluntary urination, and use of semen extenders. None of these efforts reliably yielded a quality ejaculate. Administration of imipramine hydrochloride (1.2 mg/kg of body weight, PO, 4 hours prior to semen collection) was initiated in an attempt to enhance bladder neck closure during ejaculation. This treatment, combined with voluntary urination prior to ejaculation, resulted in ejaculates containing little or no urine. Using this protocol, 19 of 20 mares bred during the subsequent 2 years became pregnant. By the third year, the bladder dysfunction had progressed, and the urospermia was no longer manageable. Bladder catheterization, followed by manual expression of the bladder per rectum, were necessary prior to each semen collection to obtain a urine-free ejaculate. Three-and-a-half years after initial examination, transitional cell carcinoma of the bladder with metastasis was identified, and the stallion was euthanatized. It is not known whether the transitional cell carcinoma was related to the dysfunctional bladder. Imipramine hydrochloride did not eliminate, but did reduce, the frequency and degree of urospermia in the affected stallion for approximately 2 years.
D000008:Abdominal Neoplasms / Q000556:secondary / Q000662:veterinary; D018759:Adrenergic Uptake Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D002295:Carcinoma, Transitional Cell / Q000209:etiology / Q000473:pathology / Q000662:veterinary; D005260:Female; D006734:Horse Diseases / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D006736:Horses; D007099:Imipramine / Q000494:pharmacology / Q000627:therapeutic use*; D008175:Lung Neoplasms / Q000556:secondary / Q000662:veterinary; D008297:Male; D011247:Pregnancy; D018873:Pregnancy Rate; D012661:Semen / Q000737:chemistry; D013125:Spinal Neoplasms / Q000556:secondary / Q000662:veterinary; D001743:Urinary Bladder / Q000187:drug effects* / Q000503:physiopathology; D001745:Urinary Bladder Diseases / Q000188:drug therapy / Q000503:physiopathology / Q000662:veterinary*; D001749:Urinary Bladder Neoplasms / Q000209:etiology / Q000473:pathology / Q000662:veterinary; D014546:Urinary Catheterization / Q000662:veterinary; D016055:Urinary Retention / Q000188:drug therapy / Q000503:physiopathology / Q000662:veterinary; D014556:Urine; D014743:Videotape Recording
D018759:Adrenergic Uptake Inhibitors; D007099:Imipramine